USP Comments to FDA Public Meeting: “The Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access” Regarding Generic Medicines. Comments were submitted 7-18-2017.
Public Policy
USP Comments to FDA Public Meeting: “The Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access” Regarding Generic Medicines. Comments were submitted 7-18-2017.